HighTide Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $107M
Overview
Developing HTD1801, an oral multi-targeted therapy for serious metabolic and liver diseases like MASH and type 2 diabetes.
Metabolic
Technology Platform
The company's platform is based on developing novel ionic co-crystal drugs, like HTD1801, that combine known active molecules to create multi-targeted therapies with improved efficacy and safety profiles.
Funding History
1Total raised:$107M
Series B$107M
Opportunities
Success in its Phase 3 trials could establish HTD1801 as a leading oral therapy for the massive global MASH and metabolic disease markets.
Risk Factors
Clinical failure in late-stage trials for its lead asset would be catastrophic, given the company's concentrated pipeline and the high historical failure rate in MASH.
Competitive Landscape
Operates in the fiercely competitive MASH space against large pharma (Madrigal, Novo Nordisk) and other biotechs, competing on the basis of its oral, multi-targeted mechanism.